GeoVax Labs Inc. DNA/MVA Vaccine Elicits Sustained Antibody Responses to HIV

GeoVax Labs, Inc. , a biotechnology company developing vaccines to prevent and treat HIV/AIDS, today presented additional results from HVTN 205, a multicenter, randomized Phase 2a trial evaluating the safety and immunogenicity of the Company's first generation preventive HIV vaccine, at the 2013 AIDS Vaccine Meeting in Barcelona, Spain.

http://www.biospace.com/news_story.aspx?StoryID=311328&full=1